Lloyd Payne

Lloyd Payne, D.Phil., is a Venture Partner at Kineticos Life Sciences AMR Fund (KAMRA) and currently serves as Chief Executive Officer of a newly established spin-out from a U.S. university, founded through the Kineticos Foundry program, which is dedicated to developing a novel class of antibacterials.

With over 25 years of experience in drug discovery and development, Lloyd’s previous roles have included CEO at ArrePath, Global Head Anti-infectives at Evotec, and founding CEO at Euprotec (acquired by Evotec).

Dr. Payne has a background in medicinal chemistry and has contributed to a broad range of therapeutic programs across oncology, inflammation, and infectious diseases. He also serves as an advisor to leading sector-specific anti-infective investment funds, including the AMR Action Fund and the Novo Foundation REPAIR Impact Fund, and provides scientific guidance to several biotech companies in the AMR and antibiotics space.